Last reviewed · How we verify
NCT06950931: (uPTM-FetA)
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
trial testing uPTM-FeA in Transplant Recipient (Kidney) in 86 participants. Enrolling by invitation.
25 July 2025
Quick facts
| Lead sponsor | University Hospital, Martin |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 86 |
| Start date | 25 June 2024 |
| Primary completion | 25 July 2025 |
| Estimated completion | 25 July 2025 |
| Sites | 1 location across Slovakia |
Drugs / interventions tested
- uPTM-FeA
Conditions studied
- Transplant Recipient (Kidney) — all drugs for Transplant Recipient (Kidney) →
- Primary Kidney Transplantation — all drugs for Primary Kidney Transplantation →
Sponsor
University Hospital, Martin
Who can join
18 and older, any sex, with Transplant Recipient (Kidney) or Primary Kidney Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors, therefore they are considered insufficient. Urinary post-translationally modified fetuin A (uPTM-FeA) appears to be a promising biomarker for the early detection of impaired renal function. Increased values were detected in patients with diabetic kidney disease, acute kidney injury and interstitial fibrosis/tubular atrophy. Patients after kidney transplantation will be included in our analysis, in which the value of uPTM-FeA at the time of kidney graft biopsy performing (indication/ protocolar) and 6th months after biopsy. The study will also include the patients with chronic kidney disease after renal biopsy, when the value of uPTM-FeA be examined and then 6 months after renal biopsy. The analysis will be correlated with the basic characteristics of the donor and recipient, with the results of protocol or indication biopsy, rejection, level and dose of immunosuppression and parameters detecting renal function. The analysis will be correlated with the histopatology result of kidney biopsy. The study also include patients with chronic kidney disease or acute kidney injury, who undergo renal biopsy. The value of uPTM-FeA be examined at the time of kidney biopsy and then 6 months after and correlated with the basic laboratory parametres and the results biopsy. The aim of our study is to confirm the reliability of uPTM-FeA as a marker of kidney graft failure with the perspective of including uPTM-FeA examination in routine examination methods. Early detection of kidney graft failure can help save not only the graft, but also prolong the patient's life. And the second aim is correlated the value of uPTM-FeA with the severity of acute kindey injury and diagnosis of chronic kidney disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06950931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transplant Recipient (Kidney)
Currently open trials in the same condition.
- NCT06701825 — Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus · Phase 4 · recruiting
- NCT06972069 — Tolerance Through Mixed Chimerism (Sip-Tego) · EARLY_PHASE1 · recruiting
- NCT06759831 — Clinical and Immunological Outcomes of Living and Deceased Donor Transplantation · recruiting
Other University Hospital, Martin trials
Trials by the same sponsor.
- NCT07274462 — DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation) · Phase 4 · active not recruiting
- NCT07338929 — Physical Performance Assessment in Kidney Transplant Evaluation · recruiting
- NCT06929637 — Amino Acid Infusion in Kidney Transplant Recipients · NA · not yet recruiting
- NCT07081126 — Daratumumab for Late Antibody-Mediated Rejection · NA · recruiting
- NCT07055984 — Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06950931 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Martin
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06950931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing